Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886248 | 0.86 | LMNA (0.44) | LMNAGAATYK2NFKB1KDM4E | |
| SCHEMBL504216 | 0.81 | CA12 (0.46) | LMNAGAATYK2NFKB1ALDH1A1 | |
| SCHEMBL8447031 | 0.79 | ALDH1A1 (0.48) | LMNAGAATYK2NFKB1KDM4E | |
| SCHEMBL7878426 | 0.79 | MAOB (0.42) | LMNAGAATYK2NFKB1KDM4E | |
| SCHEMBL1995318 | 0.79 | THRB (0.48) | LMNAGAATYK2NFKB1KDM4E | |
| SCHEMBL23908702 | 0.77 | ALDH1A1 (0.51) | LMNAGAATYK2NFKB1ALDH1A1 | |
| SCHEMBL16857987 | 0.77 | LMNA (0.41) | LMNAGAATYK2NFKB1KDM4E | |
| SCHEMBL4083398 | 0.77 | CA2 (0.40) | LMNAGAATYK2NFKB1KDM4E | |
| SCHEMBL3374645 | 0.77 | TAS2R14 (0.46) | LMNAGAATYK2MEN1KMT2A | |
| SCHEMBL16888475 | 0.76 | ALDH1A1 (0.42) | LMNAGAATYK2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| EP-3179991-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| EP-2019671-B1 | INTERMEDIATES FOR THE PREPARATION OF BIVALENT SMAC MIMETICS | UNIV MICHIGAN (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2139490-B1 | DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8664212-B2 | Diazo bicyclic Smac mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-04 | — | — | US | disclosed |
| US-8557812-B2 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-15 | — | — | US | disclosed |
| US-6495522-B1 | PREVENTING APOPTOTIC CELL DEATH IN WHICH THE LOSS OF CELLS, TISSUES OR ENTIRE ORGANS OCCURS | CYTOVIA, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1165490-A4 | SUBSTITUTED 2-AMINOBENZAMIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1212295-A1 | SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020058631-A1 | Caspase inhibitors and the use thereof | CYTOVIA, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6355618-B1 | ENZYME INHIBITORS | CYTOVIA, INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1177168-A1 | CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1165490-A1 | SUBSTITUTED 2-AMINOBENZAMIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001016093-A1 | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000061542-A1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000055114-A1 | SUBSTITUTED 2-AMINOBENZAMIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | LMNA 3807/4885GAA 2112/4885TYK2 95/4885 |
| US-20020058631-A1 | Caspase inhibitors and the use thereof | CASP1, CASP3, CASP10 | LMNA 686/4885GAA 1099/4885TYK2 3191/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | LMNA 3807/4885GAA 2112/4885TYK2 95/4885 |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | LMNA 3807/4885GAA 2112/4885TYK2 95/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | LMNA 3807/4885GAA 2112/4885TYK2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.